XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.23.3

FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2023 | Dec. 31, 2022
FAIR VALUE MEASUREMENTS |  |
Schedule of key inputs into the monte carlo simulation for the private placement warrants | The fair value of the Series B-2 Tranche Liability was determined using a Binomial Tranche Model. Both models incorporated the following significant assumptions for the respective valuation dates: |
Schedule of changes in the level 3 fair value of warrant liabilities | The following tables summarize the changes in fair value of our outstanding earnout liability in the nine months ended September 30, 2023. The warrant and earnout liability were not present in the nine months ended September 30, 2022. ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Fair Value at |  | Change in |  | ​ | ​ |  | Net Transfer |  | Fair Value at
Level 3 | ​ | December 31, | ​ | Unrealized | ​ | Issuances | ​ | In (Out) of | ​ | September 30,
Liabilities | ​ | 2022 | ​ | (Gains) Losses | ​ | (Settlements) | ​ | Level 3 | ​ | 2023
Contingent earnout liability | ​ | $ | — | ​ | $ | (19,904) | ​ | $ | 28,927 | ​ | $ | — | ​ | $ | 9,023
The following tables summarize the changes in fair value of our outstanding warrant and tranche liabilities measured using Level 3 inputs in the nine months ended September 30, 2023 and 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Fair Value at |  | Change in |  | ​ | ​ |  | Net Transfer |  | Fair Value at
Level 3 | ​ | December 31, | ​ | Unrealized | ​ | Issuances | ​ | In (Out) of | ​ | September 30,
Liabilities | ​ | 2021 | ​ | (Gains) Losses | ​ | (Settlements) | ​ | Level 3 | ​ | 2022
Warrant liability | ​ | $ | 391 | ​ | $ | (19) | ​ | $ | — | ​ | $ | — | ​ | $ | 372
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Fair Value at |  | Change in |  | ​ | ​ |  | Net Transfer |  | Fair Value at
Level 3 | ​ | December 31, | ​ | Unrealized | ​ | Issuances | ​ | In (Out) of | ​ | September 30,
Liabilities | ​ | 2022 | ​ | (Gains) Losses | ​ | (Settlements) | ​ | Level 3 | ​ | 2023
Warrant liability | ​ | $ | 369 | ​ | $ | — | ​ | $ | (369) | ​ | $ | — | ​ | $ | —
Series B-2 tranche liabilities | ​ | $ | 4,702 | ​ | $ | (3,200) | ​ | $ | (1,502) | ​ | $ | — | ​ | $ | —
Series B-3 Warrant liabilities | ​ | $ | 15,819 | ​ | $ | (311) | ​ | $ | (15,508) | (1) | $ | — | ​ | $ | —
(1) | This amount includes settlements of $25,409, and final net exercise of $4,800, transferred to convertible preferred stock, offset by issuances of $14,701
| ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value at | ​ | Change in | ​ | ​ | ​ | ​ | Net Transfer | ​ | Fair Value at
Level 3 | ​ | December 31, | ​ | Unrealized | ​ | Issuances | ​ | In (Out) of | ​ | December 31,
Liabilities |  | 2020 |  | (Gains) Losses |  | (Settlements) |  | Level 3 |  | 2021
Warrant liability | ​ | $ | 3,399 | ​ | $ | 379 | ​ | $ | (3,387) | (1) | $ | — | ​ | $ | 391
Put option liability | ​ | $ | 5,140 | ​ | $ | 70 | ​ | $ | (5,210) | ​ | $ | — | ​ | $ | —
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value at | ​ | Change in | ​ | ​ | ​ | ​ | Net Transfer | ​ | Fair Value at
Level 3 | ​ | December 31, | ​ | Unrealized | ​ | Issuances | ​ | In (Out) of | ​ | December 31,
Liabilities |  | 2021 |  | (Gains) Losses |  | (Settlements) |  | Level 3 |  | 2022
Warrant liability | ​ | $ | 391 | ​ | $ | (22) | ​ | $ | — | ​ | $ | — | ​ | $ | 369
Series B-2 tranche liabilities | ​ | $ | — | ​ | $ | (1,645) | ​ | $ | 6,347 | ​ | $ | — | ​ | $ | 4,702
Series B-3 warrant liabilities | ​ | $ | — | ​ | $ | 3,853 | ​ | $ | 11,966 | ​ | $ | — | ​ | $ | 15,819
​ (1)This amount includes settlements of $3,397, reduced by issuances of $10.
MedTech Acquisition Corp |  |
FAIR VALUE MEASUREMENTS |  |
Schedule of company's assets that are measured at fair value on a recurring basis |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | December 31, |  | December 31,
​ | ​ | Level |  | 2022 |  | 2021
Assets: |  |  |  | ​ |  | ​ | ​ | ​
Cash and investments held in Trust Account |  | 1 | ​ | $ | 19,827,884 | ​ | $ | 250,007,295
Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Warrant Liabilities – Public Warrants | ​ | 1 | ​ | $ | 666,667 | ​ | $ | 4,333,333
Warrant Liabilities – Private Placement Warrants | ​ | 3 | ​ | $ | 394,667 | ​ | $ | 2,565,333
Schedule of key inputs into the monte carlo simulation for the private placement warrants |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | December 31, | ​ | December 31, | ​
​ |  | 2022 |  | 2021 |
Exercise price | ​ | $ | 11.50 | ​ | $ | 11.50 | ​
Stock price | ​ | $ | 10.03 | ​ | $ | 9.88 | ​
Volatility | ​ |  | 6.40 | % |  | 9.60 | %
Term | ​ |  | 5.25 | ​ |  | 5.16 | ​
Risk-free rate | ​ |  | 3.91 | % |  | 1.27 | %
Dividend yield | ​ |  | 0.00 | % |  | 0.00 | %
Schedule of changes in the level 3 fair value of warrant liabilities |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Private | ​ | ​ | ​ |  | Warrant
​ | ​ | Placement | ​ | Public | ​ | Liabilities
Fair value as of December 31, 2021 | ​ | $ | 2,565,333 | ​ | $ | — | ​ | $ | 2,565,333
Change in fair value |  | ​ | (2,170,666) |  | ​ | — |  | ​ | (2,170,666)
Fair value as of December 31, 2022 | ​ | $ | 394,667 | ​ | $ | — | ​ | $ | 394,667
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Private | ​ | ​ | ​ | Warrant
​ |  | Placement |  | Public |  | Liabilities
Fair value as of December 31, 2020 | ​ | $ | 5,476,000 | ​ | $ | 9,166,666 | ​ | $ | 14,642,666
Change in fair value | ​ |  | (2,910,667) | ​ |  | (4,833,333) | ​ |  | (7,744,000)
Transfer to level 1 | ​ |  | — | ​ |  | (4,333,333) | ​ |  | (4,333,333)
Fair value as of December 31, 2021 | ​ | $ | 2,565,333 | ​ | $ | — | ​ | $ | 2,565,333

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=tlsi_MedtechAcquisitionCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |